Rituximab therapy for childhood Evans syndrome

The safety and efficacy of rituximab have been retrospectively assessed in 17 children with Evans syndrome. Patients received 4 or 3 weekly doses of rituximab (375 mg/m2 per dose) associated with prednisone, alone (14 patients) or associated with other immunosuppressive drugs. Complete or partial remission of at least one cytopenia was achieved in 13 out of the 17 patients (76%), and lasted in 11 of them with a mean follow-up of 2.4 years (range 0.5–7 years). Steroid therapy was stopped or tapered at 50–100% of the baseline dosage in all long-term responders. Moderate side effects and infection occurred only in 4 and 1 children respectively.

[1]  Kenneth G. C. Smith,et al.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. , 2006, Arthritis and rheumatism.

[2]  E. Haddad,et al.  Rituximab therapy for childhood-onset systemic lupus erythematosus. , 2006, The Journal of pediatrics.

[3]  M. Loh,et al.  Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. , 2006, Blood.

[4]  I. Roberts,et al.  Management of Evans syndrome , 2006, British journal of haematology.

[5]  B. Bader-Meunier,et al.  Severe hematological side effects following Rituximab therapy in children. , 2006, Haematologica.

[6]  Y. Bertrand,et al.  Syndrome d'Evans : étude rétrospective de la société d'hématologie et d'immunologie pédiatrique (36 cas) , 2005 .

[7]  G. Leverger,et al.  [Evans' syndrome: a retrospective study from the ship (French Society of Pediatric Hematology and Immunology) (36 cases)]. , 2005, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[8]  P. Woo,et al.  B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. , 2005, Arthritis and rheumatism.

[9]  P. Jubinsky,et al.  Successful treatment of a patient with mixed warm and cold antibody mediated Evans syndrome and glucose intolerance , 2005, Pediatric blood & cancer.

[10]  M. Dougados,et al.  Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases , 2004, Annals of the rheumatic diseases.

[11]  J. Bussel,et al.  Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. , 2005, The Journal of pediatrics.

[12]  G. Silverman,et al.  Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. , 2003, Arthritis and rheumatism.

[13]  S. Perrotta,et al.  Rituximab for the treatment of refractory autoimmune hemolytic anemia in children. , 2003, Blood.

[14]  I. Sanz,et al.  The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus , 2003 .

[15]  A. Fischer,et al.  Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Kennedy,et al.  An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab. , 2003, Blood.

[17]  A. Fischer,et al.  Treatment of childhood autoimmune haemolytic anaemia with rituximab , 2001, The Lancet.

[18]  Y. Ravindranath,et al.  The spectrum of Evans’ syndrome , 1997, Archives of disease in childhood.

[19]  Winfred C. Wang,et al.  Evans Syndrome: Results of a National Survey , 1997, Journal of pediatric hematology/oncology.

[20]  C. Pui,et al.  Evans syndrome in childhood. , 1980, The Journal of pediatrics.

[21]  K. Takahashi,et al.  Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. , 1951, A.M.A. archives of internal medicine.